Podcasts about hcc

What do you do when Y-90 doesn't deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction04:24 - Treatment Nonresponse Troubleshooting06:12 - Navigating Y90 Through Replaced Arteries09:09 - Mitigating Vasospasm in Embolization13:31 - What is ‘PREDATr'?21:12 - Dual Balloon Microcatheter System23:37 - Gelfoam Techniques and Application26:06 - Embolization Agents Preferences36:16 - Concerns with Cystic Artery Treatment and Biliary Stents42:15 - Prophylactic Antibiotics 44:29 - Utilizing High Lung Shunts49:28 - Wrap Up and Credits --- More about this episode The conversation begins with case-based examples of HCC radioembolization, focusing on how to assess treatment response and troubleshoot nonresponsive cases. They discuss how to interpret SPECT findings, identify missed tumor supply with cone-beam CT, and overcome obstacles such as vasospasm, extrahepatic feeders, and challenging arterial anatomy. They introduce the PREDATr technique (proximal radioembolization enabled by distal angiozone truncation) and explain how tools like gelfoam, balloons, and retrievable coils can preserve healthy liver tissue and improve microsphere delivery. The episode also addresses managing biliary stents, using antibiotic prophylaxis, and strategies for handling high lung shunts, making it a practical resource for anyone navigating the complexities of Y-90 treatment. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Meditação de 15 de junho de 2026Fonte: Manancial, publicação das Mulheres Batistas (MB)Título: Refúgio seguro nas tempestadesTexto: Daniel Braga; leitura e edição: Samuel LimaBG: Sê minha vida (363 HCC) - "Be thou my vision, com arranjo de Josh Snodgrass.

HEALTH NEWS   Ginger Supplementation Reduces Muscle Soreness, Review Finds Artificially sweetened and sugar-sweetened beverage intake and risk of liver cancer Plant-based quinoa burgers reduce post-meal blood sugar spikes Sleep and exercise may curb heart risk from mutant white blood cells Pregnant women may reduce key health risk through less sitting, more light exercise     Ginger Supplementation Reduces Muscle Soreness, Review Finds Old Dominion University, June 4 2026 (Natural News)     A review published in Nutrition Reviews found that consuming 2 grams of ginger daily for 11 consecutive days before exercise reduced delayed-onset muscle soreness (DOMS) by 23% to 25%.   The review examined multiple placebo-controlled studies and found that single doses taken just before exercise did not produce significant pain reduction, but consistent daily intake over the 11-day period yielded measurable results.   DOMS typically occurs 24 to 72 hours after exercise and is a common reason individuals skip subsequent workouts. In two placebo-controlled studies reviewed, participants consumed 2 grams of either raw or heat-treated ginger daily for 11 days before performing eccentric exercise, which lengthens muscles under tension. The effective dose identified in the review was 2 grams per day, roughly equivalent to one teaspoon of fresh grated ginger.   Artificially sweetened and sugar-sweetened beverage intake and risk of liver cancer Yale University, National Cancer Institute, Boston University, June 10 2026 (Eurekalert) Are artificially sweetened beverage (ASB) and sugar-sweetened beverage (SSB) intakes associated with risk of liver cancer overall and by subtype (hepatocellular carcinoma [HCC] and intrahepatic cholangiocarcinoma [ICC])? In this pooled analysis of 11 prospective cohort studies comprising 1,518,411 adults, SSB intake per 1-beverage/day increment was associated with increased risk of HCC and ICC, whereas ASB intake was not associated with liver cancer overall or by subtype. There was no evidence of effect modification by diabetes status.     Plant-based quinoa burgers reduce post-meal blood sugar spikes Federal University of Golas (Brazil), June 10 2026 (News-Medical) A study published in ACS Nutrition Science suggests that a plant-based burger made from baru pulp and red quinoa could reduce post-meal blood glucose responses in healthy adults. Red quinoa (Chenopodium quinoa Willd.) is a pseudocereal that is rich in protein, fiber, and micronutrients. It provide spolyphenols that have been shown to slow gastric emptying and overall digestion, and may reduce enzymatic degradation of carbohydrates in the gut. This would influence the rate at which glucose is absorbed into the bloodstream after a meal, altering the GI. The authors of this pilot study examined GI in a small sample of eight volunteers after consuming two plant-based burgers: one made with baru pulp and red quinoa, and the other with red quinoa alone.  All three foods produced their highest blood glucose levels 30 minutes after consumption. The glucose reference food generated the largest peak at 174 mg/dL, while the baru pulp–red quinoa and red quinoa burgers reached substantially lower peaks of 118 mg/dL and 120 mg/dL, respectively. By 120 minutes, blood glucose levels had declined in all groups. Compared with the glucose reference, both plant-based burgers caused only modest increases in blood glucose relative to fasting levels: 15.5% for the red quinoa burger and 18% for the baru pulp–red quinoa burger.   Sleep and exercise may curb heart risk from mutant white blood cells Mount Sinai Hospital, June 10. 2026 (Medical Xpress) Healthy sleep and regular exercise can work to counteract genetic mutations in white blood cells that are associated with cardiovascular disease and are most common among older people, Mount Sinai researchers have found. In a study published in Nature, the team reported for the first time that sufficient sleep and exercise can help reduce the cancer-like cell expansion and atherosclerotic risk linked to mutations that spontaneously occur in white blood cells. These mutations accumulate over our lifetimes and occur most often in hematopoietic stem cells, which are the cells in bone marrow that make blood cells, including macrophages and monocytes, immune cells that help defend the body. When these cells develop mutations, they start to proliferate, multiplying faster than they should, and become more inflammatory, irritating or damaging tissues in the body. This condition, known as clonal hematopoiesis (CH), is detectable in a quarter of people over age 70 and half of people over 80, though it is infrequent in young, healthy people. Healthy sleep and exercise was found to selectively influence immune cells with clonal hematopoiesis mutations, repressing their proliferative programming and expansion, as well as their ability to promote the formation of harmful plaque in the arteries of the heart. The findings reveal that CH mutant cells are malleable and selectively responsive to lifestyle behavior in a way that can mitigate atherosclerotic risk. Mount Sinai researchers discovered that moderate-to-vigorous physical activity was associated with a reduced incidence of gene-specific CH and fewer mutant cells in the blood. Sufficient sleep and exercise "turned off" the detrimental effects of rogue Jak2 and Tet2 mutant CH hematopoietic stem cells in the bone marrow, decreasing their ability to proliferate and grow, a precancerous process known as "clonal expansion.   Pregnant women may reduce key health risk through less sitting, more light exercise University of Iowa, June 10 2026 (Eurekalert)   Women who engage in light physical activity and lessen their sedentary time may significantly reduce the risk of key health problems during pregnancy, according to a new University of Iowa-led study. Researchers examined the daily behaviors of 470 pregnant women across all stages of pregnancy. Each participant wore a monitor that measured physical activity in 24-hour cycles and another monitor that recorded the time they spent asleep. Based on observational data collected from the study's participants, the researchers propose a “Goldilocks Day”-like guide for pregnant women that could reduce by nearly 30% the risk of developing hypertensive disorders of pregnancy (HDP), commonly occurring complications of pregnancy that include chronic hypertension, gestational hypertension, and preeclampsia. Those recommendations are: • Reduce sedentary time to fewer than eight hours each day. • Engage in light physical activity for at least seven hours each day. • Engage in approximately 22 minutes of moderate to vigorous physical activity, such as a brisk walk, each day. • Get nearly nine hours of sleep each night.

How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of BackTable 2026 HCC Creator Weekend™ host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y-90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y-90's role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction01:31 - Rad Lobectomy Goals and Case Discussion06:09 - Selective vs Lobar Dosing07:51 - PVE Versus Y9009:35 - Downstaging to Transplant13:03 - Patient Selection Factors19:22 - Radseg vs. Lobar Strategy22:12 - Percent Liver Treated Debate26:38 - Particle Density and Catheter Bias28:04 - Downstaging Evidence MERIT LT36:20 - Operating After Y9041:25 - Hypertrophy Timing and Readiness43:03 - Wrap Up --- More about this episode The discussion features a case of massive right-lobe HCC in a non-cirrhotic patient, with stepwise Y-90 dosing and selective retreatment leading to complete response and marked liver hypertrophy. The doctors compare radiation lobectomy with portal vein embolization (PVE), explore dosimetry advances from studies like DOSISPHERE and MERITS-LT, and stress the importance of careful mapping and patient selection. Additional topics include the pros and cons of different downstaging methods, functional imaging to assess risk, the impact of lab values and portal hypertension, and the practicalities of timing surgery after Y-90. --- Resources Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trialhttps://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211 Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortiumhttps://pubmed.ncbi.nlm.nih.gov/37532179/ --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Meditação de 07 de junho de 2026Fonte: Manancial, publicação das Mulheres Batistas (MB)Título: Abra meus olhos, Senhor!Texto: Nelson da SilvaLeitura e Edição: Samuel LimaBG: Sê minha vida (363 HCC) - "Be thou my vision, com arranjo de Josh Snodgrass.

What does it really take to run a high-volume Y-90 program that is efficient, scalable, and patient-centered? In this episode of BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and Kirema Garcia-Reyes to break down the systems, workflows, and strategies that drive successful radioembolization centers. The conversation focuses on overcoming referral and insurance delays, implementing multidisciplinary clinics, and using tools like single-session Y-90 and routine post-treatment dosimetry to reduce treatment times and improve outcomes. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction04:46 - Multidisciplinary Model on Radioembolization08:39 - Referral Pathways and Embolization Preferences13:18 - Y-90 Follow Up and Imaging15:51 - Procedure Preparation and Involvement18:00 - Dosimetry Planning and Software ROI22:59 - Analyzing Outcomes and Quality Control26:47 - Various Ways to Expedite Treatments34:04 - Wrap Up and Credits --- More about this episode The doctors discuss the importance of robust internal systems for patient selection, integration of dosimetry planning, and standardized follow-up protocols.They share insights on procedural workflows, including best practices for dosimetry ownership and equipment setup, and highlight the growing role of post-Y-90 dosimetry as both a quality control measure and a billable service. The episode also explores the order-map-treat paradigm, the impact of multidisciplinary tumor boards and clinics, and how single-session strategies are reshaping HCC care by cutting delays, reducing costs, and enhancing the patient experience. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Viral hepatitis is an ongoing public health threat, despite the long-standing availability of effective vaccines for hepatitis A and B. Here, experts Paul Kwo, MD, Jewel Mullen, MD, MPH, MPA, FACP, and Su Wang, MD, MPH, FACP, discuss how to incorporate knowledge of hepatitis A and B risk factors and disease burden into patient counseling to enhance uptake of hepatitis A and B vaccines. Topics covered include: The burden of hepatitis A and B in the United States Risk factors for infection Current evidence-based recommendations for hepatitis A and B vaccination.  Follow along with the slides here, and get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul Y. Kwo, MD Professor of Medicine Director of Hepatology Stanford University School of Medicine Stanford, California Jewel Mullen, MD, MPH, MPA, FACP Associate Professor of Population Health and Internal Medicine University of Texas at Austin Dell Medical School Austin, Texas Su Wang, MD, MPH, FACP Medical Director, Center for Asian Health & Viral Hepatitis Programs Cooperman Barnabas Medical Center/RWJBarnabas-Rutgers Medical Group Assistant Clinical Professor, Rutgers New Jersey Medical Group Florham Park, New Jersey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, Scott was joined by Rev Tamika Nelson, executive director of United Campus Ministries of Greater Houston. Rev. Nelson was ordained in the Christian Church (Disciples of Christ); has served a United Methodist Church; and now works in a campus ministry affiliated with the Presbyterian Church (USA), the Christian Church (Disciples of Christ), and the United Church of Christ. United Campus Ministry serves the UT School of Medicine, HCC locations, Texas Southern University, UHD, and Rice University.   Tamika has also participated in Houston Faith Votes, so Scott and Tamika discussed her ministry with young adults and how they are talking about our current policy climate, their leadership in the civic engagement space, and their barriers to participation.  We hope you enjoy this episode and invite a friend to listen along. If you share it in your social media, make sure to tag us! To learn more or get involved, check out Texas Impact's Action Center at texasimpact.org. Get full access to Texas Impact at texasimpact.substack.com/subscribe

Meditação de 20 de maio de 2026Fonte: Manancial, publicação das Mulheres Batistas (MB)Título: Não ore para perdoar, mas até perdoarTexto: Dayane FernandesLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "What a Friend We Have in Jesus", com arranjo de Josh Snodgrass.

A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account for liver reserve, tumor biology, and evolving biomarkers. In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, abdominal transplant surgeon Dr. Ari Cohen (Ochsner Health) and transplant hepatologist Dr. Neil Mehta (UCSF) join host Dr. Kavi Krishnasamy to map out strategies for effective multidisciplinary treatment and transplantation planning in HCC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction00:51 - Starting a Tumor Board06:39 - Building Referral Streams09:03 - Academic and Community Practice Integration14:31 - Treatment Selection Criteria20:38 - Modern HCC Biomarkers25:24 - Role of ctDNA and Biopsy29:37 - Bridging Therapy on Transplant Waitlist32:34 - Downstaging Strategy and Risks39:25 - Final Thoughts and Closing Remarks --- More about this episode The physicians discuss what it takes to build a robust tumor board, from fostering hospital buy-in to engaging leaders across specialties and utilizing virtual formats for consistent participation. The conversation explores clinical decision-making, emphasizing the integration of AFP-L3 and DCP biomarkers alongside AFP to better understand tumor biology and predict post-transplant recurrence. Dr. Mehta and Dr. Cohen also share their patient selection criteria, discussing how bilirubin, liver disease etiology, and INR influence decisions. While radiographic guidance remains central to HCC management, they highlight the growing potential of reliable ctDNA analysis and other biomarkers. The specialists conclude by emphasizing that an integrated, communicative tumor board is the most effective way to navigate the nuances of liver reserve and HCC biology to achieve the best possible patient outcomes. --- Resources Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma.https://doi.org/10.1007/s10238-025-01877-8 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Episode 223: Oncogenic Viruses Introduction Mehr: Hi everyone, welcome back to the Rio Bravo qweek podcast. Back by popular demand is Me, Mehr Boparai a third-year medical student at COMP-NW. Here with me is Jeremy Pan from COMP who is also a third-year medical student. How are you doing Jeremy? Jeremy: I'm doing great Mehr.Thanks for the kind intro; we had a fun time this morning doing street medicine and had some practice giving Toradol injections and wound dressings. So excited to be back for another podcast episode this afternoon! Mehr: This week, we are moving away from bacteria and antibiotics and diving deeper into cancer-causing viruses. Jeremy: Yes, and if you are interested at all in public health, this is one of those areas where medicine overlaps with public health in a really tangible way. I think one of the most underappreciated aspects of this topic is that we have vaccines that can prevent many of these cancers. If you told someone 50 years ago we'd be vaccinating against cancer, they probably wouldn't believe you! It's amazing to see how far medicine has come. How viruses cause cancer: Jeremy: Before jumping into specific viruses, I always think having a mechanism-based framework makes everything stick better. Mehr: Right, because they don't all cause cancer the same way. Medicine can never be easy huh? Jeremy: Yea…this career really is just a lifetime of discovery. So just to start, in broad terms, we can think of three main buckets of how viruses can cause cancer: Direct oncogenesis where viral proteins interfere with tumor suppressors like P53 and Rb. We will go over their specific mechanisms a little later in the discussion. Mehr:  Chronic inflammation where viruses cause repeated injury through production of reactive oxygen species. They also increase the chance of mutation through repeated DNA replication, leading to cancer.  Jeremy: Immune evasion or suppression leads to decreased tumor surveillance. What this means essentially is that our immune system is constantly removing abnormal cells before they become cancerous. This is completed by CD8 T cells and natural killer, or NK, cells. CD8 T cells recognize abnormal peptides presented on Major Histocompatibility Complex, or MHC, class I molecules and induce apoptosis in those cells. Mehr: And NK cells step in when cells decide to stop expressing MHC I, which abnormal cells like to hide to avoid being caught. So just to reiterate, there are two layers to dissect here: if a cell looks suspicious with an abnormal MHC, CD8 T-cells kill them. If the abnormal cell decides to hide its MHC, then the NK cell will kill it instead. Jeremy: So, for the final big picture, we can think of oncogenic viruses as either disabling tumor suppression, causing chronic damage over time through inflammation, and weakening the immune system's ability to catch cancer in time before it develops. HPV Mehr: Let's start with one of the most common viruses afflicting our population – Human Papilloma Virus otherwise known as HPV.  Jeremy: Right, this notorious virus is probably the most clinically impactful oncogenic virus. The key players HPV utilizes are proteins E6 and E7. Mehr: Right! E6 binds to and inhibits p53, which normally acts to induce cell cycle arrest, and E7 inhibits Rb, which normally acts as a tumor suppressor gene that inhibits the G1 to S phase transition in a normal cell cycle. Jeremy: So essentially, we are losing both apoptosis and losing cell cycle control at the same time. What is interesting about HPV is that persistent infection, not just exposure to the virus, is what drives cancer risk.  Mehr: Exactly, most HPV infections clear on their own, but the ones that persist are the problem. Clinically, many end up being asymptomatic. However, for high-risk infections, we can see genital warts that can itch, feel tender, or cause abnormal vaginal bleeding and discharge. Patients are sometimes not able to have a vaginal delivery because of the warts that are present along their genital tract. We can also see warts on the hands and fingers or plantar surface of our feet. Jeremy: Another interesting point is that we are also seeing a shift where there are more cases of oropharyngeal cancers in younger, non-smoking patients. This is why if we see an abnormal neck lymph node or persistent sore throat after swallowing in a young patient, HPV should definitely be on the differential.  Mehr: Screening is very important as well! We typically discover high-risk HPV infections through routine Pap smears and other HPV specific tests through DNA PCR and RNA tests. We also encourage vaccination for effective prevention of both genital warts and high-risk HPV-related cancers. There was also a study in Scotland where there were zero cases of HPV in adults who received the vaccine between 12-13 years of age! Which is crazy!  EBV HBV & HCV Mehr: Now let's shift to viruses that affect the liver, Hepatitis B virus and Hepatitis C virus. Jeremy: Both are strongly associated with hepatocellular carcinoma, but they actually get there in slightlydifferent ways. Mehr: Right. Hepatitis B is a DNA virus that can integrate directly into the host genome, which can disrupttumor suppressor genes and promote oncogenesis. Jeremy: Whereas Hepatitis C is an RNA virus, so it doesn't integrate into the host genome. Instead, it causes chronic inflammation Over time, that leads to repeated cycles of hepatocyte injury and regeneration, along withoxidative stress from reactive oxygen species, which increases the risk of DNA mutations. Mehr: One really important clinical pearl is that Hep B can actually cause hepatocellular carcinoma evenwithout cirrhosis. Whereas with Hep C, the pathway is usually chronic inflammation → fibrosis → cirrhosis → dysplasia→ cancer.  Jeremy: So, screening becomes really important for both of these viruses. For high-risk patients—like those with chronic hepatitis or cirrhosis—we typically dosurveillance with liver ultrasound every 6 months, sometimes with alpha-fetoprotein levels to see if it is elevated. Mehr: From a prevention standpoint, the Hep B vaccine is a huge win. It significantly reduces the risk ofhepatocellular carcinoma. For Hep C, we don't have a vaccine, but direct-acting antivirals can actually cure the infection andreduce long-term cancer risk, which is why we screen between ages 18-79  nowadays. Global Hep B and C account for 65% of all HCC cases! So, it makes sense that primary care itself is increasing the treatment of Hep C cases as well since it is easier to prescribe and that you want to be treated ASAP.  Jeremy: Yea, the ability to treat Hep C is so beneficial to population health. Now let's say you have a patient who develops hepatocellular carcinoma, options can include surgicalresection, liver transplantation, local therapies, or systemic treatments depending on stage.  Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!  __________________________________ References: Barry H. C. (2024). Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received at Least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age. American family physician, 110(2), 201–202. https://pubmed.ncbi.nlm.nih.gov/39172683/ Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

Parent. Sister. Friend. That was the order Andrea established with her little sister Adrienne when Adrienne was just nine years old, fresh into a new life in Los Angeles after their mother signed over custody on the day after Christmas. Andrea was twenty-two. She had not planned any of this. But she looked at her little sister and she knew. And so she laid it out simply: I have to be your parent first, then your sister, and one day when you grow up, I really hope I'm your friend. Adrienne understood. She had a painting made for Andrea's office wall. It said: Parent, Sister, Friend. That painting still hangs there today. Andrea raised Adrienne from the age of eight, working four part-time jobs to stay on her schedule, becoming a substitute teacher so she could be home when Adrienne walked in the door. She gave her stability, consistency, and a love that was fierce and steady and completely unconditional. Adrienne thrived. She found herself in high school, earned a 4.0 GPA, stopped caring what anyone else thought, and became exactly the kind of bold, vivacious, deeply caring young woman you would expect from a girl raised by someone like Andrea. And then, three weeks before the end of her freshman year of high school, Adrienne came home from school and curled up on the living room floor in pain. She could not breathe. What followed was 147 days — a diagnosis of hepatocellular carcinoma, primary liver cancer that had already spread to her lungs, caused by hepatitis B and C she had received from their mother at birth and never known about. One hundred and forty-seven days of fighting, of blue wigs and butterfly wings, of a girl who joked her way through a CAT scan and named the family cat after synthetic marijuana. Adrienne died on October 9th, 2001. She was fifteen years old. A year later, Andrea was suicidal. She had lost not just her sister but her entire purpose for being. Everything she had done, every job she had chosen, every sacrifice she had made for nearly a decade had been for Adrienne. And now Adrienne was gone. It was her partner who stopped her. He said simply: if you go ahead and kill yourself, she is never going to forgive you. And Andrea knew he was right. So she found a way to channel her grief. She called the largest liver disease nonprofit in the country, pitched herself as a volunteer, and was turned down flat. That rejection sent her searching, and what she found was a gap so large it was almost unbelievable. There was not a single organization in the United States dedicated specifically to HCC, the cancer that had killed Adrienne. So Andrea founded one. She named it Blue Faery, the Adrienne Wilson Liver Cancer Association, after Adrienne's beloved blue hair, her blue wig, and the blue butterfly wings she was buried in. The day Blue Faery was officially incorporated was December 19th, 2002. Eight years to the month from the day Adrienne came to live with her. It felt like everything was lining up. Today, Blue Faery is the leading HCC nonprofit in the country, providing education, advocacy, and community to patients and families navigating a disease that is both more common and more preventable than most people realize. Andrea has also written a memoir, Better Off Bald: A Life in 147 Days, which tells the story of the seven years she raised Adrienne and the 147 days she fought to save her. Parent. Sister. Friend. And now, advocate. Love, it turns out, does not need somewhere to go. It just becomes purpose.

Listen as Bright Ansah, patient advocate, describes his experience with being diagnosed with chronic hepatitis B as a recent immigrant to the United States and the unique barriers to treatment faced by the African immigrant community. Through his story, learn how healthcare professionals can reduce these barriers for this key population. Topics covered include: Key barriers to care for African immigrant patients Myths and misconceptions about HBV in the African immigrant community Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to program page: https://bit.ly/4uz25Vc Presenter: Bright Ansah  HBV Patient Advocate Frederick, Maryland Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

With recent updates to the Barcelona Clinic Liver Classification (BCLC), how should multidisciplinary teams adapt their treatment strategies to accommodate the newest evidence? In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, Dr. Neil Mehta of UCSF and Dr. Riad Salem of Northwestern Medicine join host Dr. Tyler Sandow to explore the complexities of hepatocellular carcinoma (HCC) therapies and the practical application of the latest global algorithms in balancing standardized therapeutic algorithms with individual patient factors. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction01:54 - HCC Case Discussion08:05 - Guest Introductions10:37 - BCLC Committee and 2025 Update15:54 - CUSE and Tumor Board Goals17:46 - Bridging vs Curative Y9022:37 - Patient Factors in Treatment Algorithms26:41 - Liver Function and Hyperbilirubinemia Trends30:25 - HCC Treatment Decision Ownership34:36 - Radiation Segmentectomy vs Surgical Resection37:35 - BCLC B Heterogeneity41:51 - Improving HCC Risk Stratification43:48 - Final Thoughts and Closing Remarks --- More about this episode The discussion begins with an inside look at the consensus process behind the 2025 BCLC updates, highlighting the official inclusion of Y90 radioembolization as a recognized therapeutic option. The experts introduce the "CUSE" (Complexity, Uncertainty, Subjectivity, and Emotion) framework to provide a structured approach to the subjective considerations that modulate purely data-based algorithms in multidisciplinary decision-making. Dr. Salem and Dr. Mehta speak on the nuances of surgical resection versus radiation segmentectomy in a case-based discussion, highlighting how factors such as portal hypertension, patient age, and etiology of cirrhosis should influence treatment pathways. Finally, they underscore the paradigm shift toward pursuing complete pathonecrosis (CPN) as a primary curative goal, regardless of bridging status, and reiterate that success in HCC care is driven by continuous communication and collaboration between physicians and patients. --- Resources BCLC 2026 Updatehttps://doi.org/10.1016/j.jhep.2025.10.020 ---BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Join AONN+ Executive Director Candice Roth, MSN, RN, CENP,  and experts from the University of California, San Diego (UCSD) as they explore the complexities of managing hepatocellular carcinoma (HCC) in this latest episode of the Heart and Soul of Oncology Navigation, facilitated by the Society of Interventional Oncology.Discover the unique features that set HCC apart from other solid tumors, including its nuanced diagnosis, and learn how UCSD's multidisciplinary team approach is empowering patients and transforming HCC care for a new era. If you're a healthcare provider involved in liver cancer care or want to understand how cutting-edge collaboration enhances survival and quality of life for patients with HCC, this episode is your essential guide. Thank you to our guests from UCSD for joining us for this insightful conversation:Zach Berman, MD, Interventional RadiologistAdam Burgoyne, MD, PhD, Medical OncologistYuko Kono, MD, PhD, FAIUM, FAASLD, HepatologistSam Myers, RN, OCNResources & LinksSociety of Interventional OncologyContact Heart & Soul of Oncology Navigation- Follow AONN+ on LinkedIn, Instagram, Facebook, and YouTube- Contact us at communications@aonn.orgThanks for listening!

When a liver tumor is hard to see, the limits of conventional image guidance can become the limits of treatment. In this episode of the BackTable Podcast, Netherlands interventional oncologist Dr. Maarten (M.L.J.) Smits shares a step-by-step walkthrough of the new hepatic arteriography and C-arm CT–guided ablation (HepACAGA) technique, punctuated with a real-world case series at the end. Find out how intra-arterial contrast, cone-beam CT, and 3D needle guidance can improve tumor conspicuity, targeting accuracy, and ablation margin assessment within a single angiography suite. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:55 - Netherlands Tech Access04:31 - Origin of HepACAGA07:14 - Why Use a Catheter?11:24 - Tools and Setup13:13 - Catheters and Devices17:06 - Contrast Protocol Basics22:51 - Targeting and Needle Guidance31:09 - Patient Selection35:56 - Extra Benefits and Multimodal39:58 - Workflow and Outcomes46:14 - Evidence and Early Studies51:41 - Rethinking Size Cutoffs57:54 - HCC Case Walkthrough01:02:27 - Hard-to-See Metastasis01:06:22 - Margin Driven Reablation01:11:04 - Bleeding and Embolization01:16:05 - Renal ACAGA Expansion01:23:31 - Adoption and Next Steps --- More about this episode Dr. Smits explains the origins of HepACAGA and why catheter-based contrast delivery can meaningfully change ablation planning, particularly for small lesions, poorly visualized tumors, and cases where ultrasound or conventional CT guidance may be insufficient. He walks through the practical setup, including catheter positioning, contrast dilution, timing protocols, needle navigation, apnea/end-expiration technique, and built-in fusion for immediate ablation verification. He also describes how the angio suite environment supports multimodal treatment, including intraprocedural embolization when bleeding occurs or when additional transarterial therapy is needed. The episode also examines early outcomes from Dr. Smits' group, including a reported reduction in local recurrence from approximately 25% to 5%, with a modest increase in procedure time. Case examples include HCC, small colorectal liver metastases, margin-driven re-ablation, hemorrhage management, and extension of the ACAGA concept to renal tumors (RenACAGA). --- Resources Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablationhttps://pubmed.ncbi.nlm.nih.gov/37704863/ Renal Arteriography and C-arm CT-Guided Ablation (RenACAGA) for Thermal Ablation of Challenging Renal Tumorshttps://pubmed.ncbi.nlm.nih.gov/40295401/ --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Meditação de 01 de maio de 2026Fonte: Manancial, publicação das Mulheres Batistas (MB)Título: Da morte para a vidaTexto: Fabrício FreitasLeitura e Edição: Samuel LimaBG: O grande amigo (165 HCC) - "In the garden", com arranjo de Josh Snodgrass)

In this replay episode from 2 years ago, we delve into the world of adult congenital heart disease to review the topic of liver disease in the Fontan patient and specifically, hepatocellular carcinoma (HCC). What is the prevalence of this disease in the Fontan single ventricle adult patient? How effective are scores like the MELD-XI or Fibrosis-4 Index at identification of HCC in the Fontan patient? How should the Fontan adult patient be surveilled for this form of cancer? What evidence is there that earlier identification of HCC is associated with better outcomes? What may prove to be the most important factor in protection of the liver in the Fontan patient? Dr. Yuli Kim, Director of the ACHD program at The University of Pennsylvania shares her deep insights this week into this important topic.DOI: 10.1093/eurheartj/ehad788

What happens when you ask clinicians to hit dozens of quality metrics but never explain why those metrics matter or how to manage them? Kenneth Botelho, founding program director of the Doctor of Medical Science program at the College of St. Scholastica, joins to discuss his KevinMD article, "Value-based care workforce: Bridging the gap in clinical education," and why medical education still trains you to treat one patient at a time in a world that demands population health thinking. He breaks down the disconnect between fee-for-service training and value-based care realities, from dashboard management and HCC coding to compensation tied to screening rates you were never taught to influence. You will hear why this knowledge gap fuels burnout and early career attrition, what PA and NP programs are starting to do about it, and how postgraduate training could give clinicians the framework they need to regain control over their day-to-day work. If you have ever felt graded on a system no one explained to you, this episode will change how you see your role in it. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Read the full article at: https://oncdata.com/exploring-ai-helioliver Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company's AI-powered blood test, HelioLiver, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult.In this DeepDive Webinar, you'll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease. This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive.Learning ObjectivesWhat are strategies to optimise surveillance and early diagnosis of hepatocellular carcinomaWhat are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy)Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapyFacultyManon Allaire - ModeratorFabio Piscaglia - SpeakerAntonio D'Alessio - SpeakerAnna Saborowski - Speaker

Im Rahmen dieser Folge beschäftigen wir uns vornehmlich mit dem HCC und dem intrahepatischen CCC als Hauptvertreter der primären Lebertumoren. Wir diskutieren Diagnostik und Therapie und arbeiten heraus, warum jeder primäre Lebertumor mindestens einmal in einem Zentrum vorgestellt werden sollte.

President Trump's emergency authorization of $23 billion in Gulf arms sales and massive defense spending increases are creating a windfall for military contractors. The defense industrial complex is experiencing its biggest expansion since the Cold War era.Today's Stocks & Topics: Tapestry, Inc. (TPR), Market Wrap, CVS Health Corporation (CVS), Applied Materials, Inc. (AMAT), Alternative Investment: Ground-floor, Defense Spending Boom: Military Contractors Hit the Jackpot, Warrior Met Coal, Inc. (HCC), The Bond Market, Kinsale Capital Group, Inc. (KNSL), VICI Properties Inc. (VICI), The Top 1%.Introducing our Third Annual InvestTalk Market Madness! Join the mayhem before May 18th at 11:59 pm PST for the chance to win $1,500! Fill out your bracket below: https://kppfinancial.com/investtalk-madnessOur Sponsors:* Check out Anthropic: https://claude.ai/invest* Check out Pebl: https://hipebl.ai* Check out Progressive: https://progressive.com* Check out Quince: https://quince.com/INVESTAdvertising Inquiries: https://redcircle.com/brands

How would you approach a town hall meeting about the future of the HCC campus for the Rays development

Full article: Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018 Should an enhancing capsule be handled differently from other LI-RADS major features? Jordan Kondo, MD, discusses this AJR article by Choi et al. that explores the impact on CT-based HCC diagnosis of proposed modified LR-5 criteria that give an enhancing capsule the same priority as other major features.

Wait…what happened to the iconic "HCC"? In this episode of the "Money" Market Podcast, host Owen LaFave and Hillsborough College President Dr. Ken Atwater unpack why Hillsborough College dropped "Community" from its name and what that means for Tampa's economic future. From workforce pipelines – FinTech, AI, healthcare, and even drone technology – Hillsborough College is fueling Tampa Bay's workforce and innovation ecosystem. Plus, plot twist, Hillsborough College just entered into a Memo of Understanding (MOU) with the Tampa Bay Rays to explore building a new stadium and mixed-use district on the Dale Mabry campus, potentially creating thousands of jobs and redefining the campus footprint. Ken shares how the college partners directly with major employers, responds to real-time industry needs, and trains talent for jobs that exist right now. This conversation also tackles affordability, enrollment growth, and why two-year colleges educate more Floridians than state universities. Owen and Ken address the Dale Mabry campus headline buzz and what a potential Rays development could mean for students and the region. With a booming $1.3B economic impact and tuition frozen for a decade, Hillsborough College is quietly doing some of the most important work in the Bay area. If you care about jobs, growth, and where Tampa Bay is headed next, you won't want to miss this episode.   WATCH NEXT: THE HIDDEN COST OF GROWTH IN TAMPA WITH GARRETT GRECO https://youtu.be/B8KrG3r6mtY SUBSCRIBE: https://www.youtube.com/channel/UCz_7yNs7dOuyKApAkohqJIQ   Follow The "Money" Market Podcast here:  Spotify: https://open.spotify.com/show/6e7E0DaJZQkuw339G7nGI4?si=27d047641a1d4b17 Apple Podcasts: https://podcasts.apple.com/us/podcast/the-money-market-podcast/id1733948143 Instagram: https://www.instagram.com/moneymarketpodcast Facebook: https://www.facebook.com/moneymarketpodcast Website: https://moneymarketpodcast.com   The Bank of Tampa | Member FDIC

Rick Stroud and Steve Versnick on the Tampa Bay Lightning's comeback win over the Sabres as they have points in 19 of their last 20 games. Nikita Kucherov had another 4-point night and Darren Raddysh continues to bomb away from the point. Plus Rob Manfred and Governor Ron DeSantis support the Rays stadium at HCC in a press conference on Tuesday, Tom Moore packs his back to leave Tampa as retirement begins and we answer your mailbag question on the Bolts trade deadline needs Hosted on Acast. See acast.com/privacy for more information.

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down new research on liver transplantation, hepatocellular carcinoma (HCC), and the ongoing evolution of surveillance strategies in chronic liver disease. Drawing on their extensive experience as transplant hepatologists, Brown and Reau place new data into practical context, highlighting where evidence may meaningfully inform practice and where unanswered questions remain.Key episode timestamps:0:00:00 – Introduction0:00:19 – Frailty & Transplant Evaluation0:02:54 – How Centers Use Frailty Measures0:04:37 – Practicalities of the Six‑Minute Walk0:06:10 – MELD 3.0 and Sex/Size Disparities0:08:42 – Exception Points & Size Constraints0:10:05 – Need for a Dynamic MELD System0:10:19 – Immunotherapy as Bridge/Downstaging for HCC0:13:34 – Real‑World Use of IO Around Transplant0:15:22 – Managing Rejection Risk0:19:03 – MASLD Population & Surveillance Gaps0:20:21 – Adherence to HCC Surveillance0:22:42 – Practical Barriers: AFP, Ultrasound, Radiology Reports0:24:02 – Shift Toward Blood-Based Surveillance0:26:01 – How AFP-L3 and DCP Are Used in Practice0:27:39 – Rising AFP, Imaging Strategy & Broader Trend to Blood Tests0:28:27 – Guidelines vs Real-World Practice0:29:37 – Closing Thoughts on Guidelines & Early Detection

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions.Key episode timestamps:0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers.0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease.0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed.0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group.0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues.0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early HCC.

Over Under, HCC update, and a QB redraft

Rich Hollenberg has a Happy Birthday message for Doug and thoughts on the HCC build

Rick Stroud and Steve Versnick on the news the Mike McDaniel is going to be the next Offensive Coordinator of the Chargers and not the Buccaneers. Plus Baker Mayfield doesn't like new Falcons Head Coach Kevin Stefanski, the Lightning win again over San Jose, NHL starting to build outdoor rink at Raymond James Stadium and HCC approves plan to pursue Rays Stadium deal. Hosted on Acast. See acast.com/privacy for more information.

Welcome to 2026, HCC!We're launching the year with a powerful new sermon series, The Shape of Sin, inspired by Timothy Keller's teachings on the seven deadly sins. Pastor Joel will open the series by examining the anatomy of sin, peeling back its layers so we can recognize it for what it truly is. Sin is more than a list of bad decisions - it subtly reshapes our hearts, redirecting what we love and redefining where we place our trust. Join us on this journey of honest reflection and renewed perspective. When we see sin clearly, it doesn't drive us into guilt - it leads us into freedom, clarity, and a deeper wonder at God's grace. As sin is revealed, grace becomes more beautiful, mercy more personal, and Jesus more worthy of our devotion. Let's begin 2026 with open eyes, humble hearts, and growing awe for the God who restores what sin distorts.

Rhodri Davies sy'n trafod y prif ddatblygiadau yn ystod 2025 gyda Glesni Phillips o HCC.

Testimony SundayThank you for joining us for a special service as we reflect on the overwhelming goodness of God. Hear heartfelt testimonies from members of HCC  - powerful stories of the Lord's faithfulness to save, provide, transform, and revive! Come, be encouraged, inspired, and reminded that God is still moving, still restoring, and still faithful in every season.

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions. Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide net. So we have a lot of large provider organizations in either CMS MSSP, ACO REACH, or a wide range of value-based care contracts with a lot of the commercial players. The Blues, Humana, Cigna, and Aetna all have value-based care plans that they have contracts with providers. So, optimizing for performance in those contracts. Anybody who works within those is our main clientele. We also have payers that are administering value-based care plans and some hospital systems as well." "If you're good at preventative healthcare, you prevent a lot of unnecessary healthcare. And so risk stratification is something that we do a lot of, and we use a lot of the standard models out there. We have Johns Hopkins embedded into our application. We have all of the different HCC models for Medicare Advantage, CDPs for Medicaid, but then also we have a suite of internal machine-learning-based models, which, I think, is funny - we've gotten to a point where there's such a thing as traditional AI, which is what it's called." #LightbeamHealthSolutions #PopulationHealth #ValueBasedCare #VBC #VBCEnablement #AI #SDOH #RemotePatientMonitoring #Providers #Payers #ACO lightbeamhealth.com Listen to the podcast here

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions. Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide net. So we have a lot of large provider organizations in either CMS MSSP, ACO REACH, or a wide range of value-based care contracts with a lot of the commercial players. The Blues, Humana, Cigna, and Aetna all have value-based care plans that they have contracts with providers. So, optimizing for performance in those contracts. Anybody who works within those is our main clientele. We also have payers that are administering value-based care plans and some hospital systems as well." "If you're good at preventative healthcare, you prevent a lot of unnecessary healthcare. And so risk stratification is something that we do a lot of, and we use a lot of the standard models out there. We have Johns Hopkins embedded into our application. We have all of the different HCC models for Medicare Advantage, CDPs for Medicaid, but then also we have a suite of internal machine-learning-based models, which, I think, is funny - we've gotten to a point where there's such a thing as traditional AI, which is what it's called." #LightbeamHealthSolutions #PopulationHealth #ValueBasedCare #VBC #VBCEnablement #AI #SDOH #RemotePatientMonitoring #Providers #Payers #ACO lightbeamhealth.com Download the transcript here

In this episode of Better Edge, Sean W. P. Koppe, MD, moderates a panel of Northwestern Medicine hepatologists as they discuss recent scientific updates from the American Association for the Study of Liver Diseases (AASLD) annual meeting held in November 2025. The conversation addresses key updates in the management of patients with cirrhosis, MASLD, HCC, alcohol liver disease, cholestatic liver diseases and autoimmune hepatitis that were presented at the meeting.

Elevate your practice from hepatocellular carcinoma (HCC) surveillance to prognosis by mastering liver-specific contrast magnetic resonance imaging (MRI) techniques. Credit available for this activity expires: [11/14/26] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/liver-mri-news-front-lines-2025a1000vg7?page=1?ecd=bdc_podcast_libsyn_mscpedu

Send us a textCan one AI system learn from every organ — and teach us something new about all of them?In this edition of DigiPath Digest #31, I explore how artificial intelligence is transforming pathology across multiple organ systems, revealing connections that help us diagnose faster, more consistently, and more accurately than ever before.From glomerulonephritis to hepatocellular carcinoma, AI is no longer confined to a single specialty — it's becoming the connective tissue between them.What's Inside:1️⃣ AI for Bladder Cancer Classification We begin with a multicenter study validating AI models for urothelial neoplasm classification using over 12,000 whole-slide images. Both CNNs and transformer models achieved high accuracy (AUC 0.983, F1 score 0.9). I discuss why the F1 score matters — and what it tells us about model balance between sensitivity and specificity.2️⃣ AI in Colorectal Cancer Care Next, we explore multimodal AI — integrating histopathology, radiology, genomics, and blood markers to modernize colorectal cancer workflows. AI now helps detect adenomas, infer microsatellite instability (MSI) from H&E slides, and predict treatment outcomes. I highlight the critical need for external validation, interpretability, and governance as AI enters clinical use.3️⃣ AI for Glomerular Nephritis Diagnosis A deep learning model trained on over 100,000 kidney biopsy images identified four nephritis types — FSGS, IgA, MN, and MCD — with over 85% accuracy. This technology could ease workloads and improve turnaround time in renal pathology. Still, I share why AI support may feel both empowering and unsettling for many pathologists.4️⃣ AI in Liver Disease (MASLD & HCC) AI is advancing noninvasive fibrosis staging and risk prediction in liver pathology. From large consortia like NIMBLE and LITMUS to predictive models for HCC therapy response, AI is moving us closer to precision hepatology. I also discuss the challenge of translating these tools from research to regulatory approval.5️⃣ Lightweight AI for Domain Generalization Finally, we look at one of pathology AI's biggest challenges: domain shift — when a model trained on one scanner or staining style performs poorly elsewhere. The new Histolite framework shows how lightweight, self-supervised models can generalize across data sources — trading some accuracy for reliability in real-world use.My TakeawayAcross every study, a single message stands out: AI isn't replacing pathologists — it's amplifying our vision. By connecting kidney, colon, liver, and bladder insights, AI is teaching us that medicine works best when it learns across boundaries.Episode HighlightsBladder cancer AI validation (06:41)Multimodal colorectal AI (12:38)Glomerular nephritis deep learning (19:29)AI in liver pathology (29:55)Domain shift & Histolite framework (38:17)Halloween wrap-up + SITC preview (46:18)Join me next time for updates from the SITC 2025 Conference, where I'll be live at Booth 415 with Hamamatsu and Biocare, discussing how AI and spatial biology are converging to drive clinical utility.#DigitalPathology #AIinHealthcare #ComputationalPathology #CancerDiagnostics #LiverPathology #RenalPathology #FutureOfMedicine #DigiPathDigestSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

This Sunday at HCC, we continue our Seven Deadly Sins series by looking at Envy — the Green-Eyed Monster. Envy begins with comparison, grows through insecurity, and ends by stealing our joy, but gratitude breaks its grip. Join us as we learn how to recognize envy in our hearts, find contentment in Christ, and celebrate the blessings God has already given us.Our regular service is at 10am on Sundays. We are located at 304 E. Austin Ave in Hutto, TX. Can't make it in person? You are welcome to join us live on Facebook or YouTube. If you need prayer or you just need someone to talk to please reach out to us at prayer@huttocommunitychurch.org.HCC Website - HCC Facebook - HCC YouTube

We will break down the historical data from Fidelity to reveal how a government shutdown truly affects the stock market, fixed income, and the broader economy, and why your long-term strategy remains the best defense. Today's Stocks & Topics: Neptune Insurance Holdings Inc. (NP), Market Wrap, Coloplast A/S (CLPBY), Games Workshop Group PLC (GMWKF), Should You Panic? The Real Impact of a Government Shutdown on Your Investments, Sanofi (SNY), Key Benchmark Numbers: Treasury Yields, Gold, Silver, Oil and Gasoline, The Shutdown, United Parcel Service, Inc. (UPS), Kenon Holdings Ltd. (KEN), The KPP Newsletter, Ramaco Resources, Inc. (METC), Warrior Met Coal, Inc. (HCC), Sign of Short-Term Market Strains.Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out Progressive: https://www.progressive.com* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

Initial Reactions to the Press Conference Excitement over finally hearing from ownership.Big question addressed: Are the Rays staying in the Tampa Bay area?New owner Patrick Zalupski confirms commitment to the region. Stadium Plans & Vision Zalupski's top priority: Building a new stadiumInspiration from Atlanta's Battery:Mixed-use development: hotels, bars, restaurants, retail, concert venues.Emphasis on creating a destination, not just a ballpark. Atlanta as the Model Turner Field to The Battery move: strategic & fan-focused.Success of moving closer to where the fanbase actually lives.Takeaway: Rays should apply the same approach. Site Challenges & Possibilities Target: 100+ acres of land – a tall order in Tampa.Areas discussed:Gaslight District – likely out.Steinbrenner Field area – possibly too small.HCC campus – enough land but unrealistic due to school presence.Raymond James area – intriguing, but complex.I-4 corridor / near Ybor / fairgrounds – promising due to accessibility.Oldsmar, outskirts, or near Lakeland – growing regions with fan potential. Data-Driven Decision Making Emphasis on studying demographics and fan location data.Go where the fans are – maximize attendance and long-term success. Timeline & UrgencyGoal: Open new stadium by 2029.Concerns about tight turnaround for:Stadium constructionMixed-use developmentHopeful, but realistic – planning must move quickly and efficiently. Interim Situation: Tropicana Field Tropicana Field remains the temporary home.Renovations help, but it's still outdated.Sympathy for the team and fans having to return there. Stadium Features Confirmed Enclosed fixed roof stadium (not retractable).Pros: AC stays.Cons: Still playing indoors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

Can you manipulate blood flow in the tumor microenvironment to optimize drug delivery? In this episode of the BackTable Podcast, interventional oncologist Dr. Zachary Berman (UC San Diego) joins host Dr. Christopher Beck to discuss real-world applications of pressure-enabled drug delivery in local, regional liver-directed therapies like TACE and Y90.---This podcast is supported by:TriSalus Life Scienceshttp://trinavinfusion.com/---SYNPOSISThe conversation begins with an overview of the tumor microvascular environment, focusing on the abnormal nature of the new vessels that feed tumors. They then discuss the genesis of pressure-enabled drug delivery and the theory behind its efficacy. Dr. Berman explains the TriNav catheter's micro-valve design, its anti-reflux properties, and how these features enhance tumor drug delivery. He walks through his own procedure technique, comparing and contrasting it to standard embolization, and details the utility of pressure-enabled drug delivery in lobar radioembolization and larger tumors. They also explore the benefits of both balloon occlusion and microvalve catheters.Real-world cases—including neuroendocrine tumors, segmental HCC, and more—illustrate the thought process around when to use specialized technologies. The episode wraps up with a discussion of the future implications for this technology in other pathologies, cost considerations, and the potential for enhancing drug delivery with innovative approaches.---TIMESTAMPS00:00 - Introduction01:39 - The Tumor Microenvironment06:59 - Pressure-Enabled Drug Delivery Explained09:37 - Technical Aspects of Pressure-Enabled Catheters21:48 - Case 1: Grade 3 Neuroendocrine Tumor34:06 - Case 2: Hepatocellular Carcinoma with Tumor and Vein36:01 - Case 3: TACE for Segmental HCC in Decompensated Cirrhosis38:58 - Case 4: Large Heterogenous Cholangiocarcinoma40:40 - Case 5: Lobar Neuroendocrine Tumor42:38 - Case 6: Segmental HCC with Central Necrosis47:52 - Best Practices and Technical Considerations57:52 - Future Directions in Pressure-Directed Embolotherapy59:48 - Conclusion and Final Thoughts---RESOURCESJVIR 2024 Jaroch et al.:https://pubmed.ncbi.nlm.nih.gov/38969336/

Tired of chasing the next “quick fix” in diet culture? In this empowering episode of Dawnversations, I sit down with wellness expert Lindsey Kaszuba to talk about breaking free from the toxic cycle of diets, fads, and unsustainable weight loss trends like Ozempic. We dive into how to finally get off the hamster wheel and start tuning into your body—based on your lifestyle, your age, and your goals. Lindsey shares how to create realistic, sustainable habits that actually work long-term. No guilt. No shame. Just real talk about food, mindset, and self-trust.If you're done with diet drama and ready for a smarter, saner approach to wellness, this episode is for you!FIND LINDSEY HERE:Lindsey's Instagram @lindseykaszubahealthHealth Club Collective is a course & community focused on helping women unlock their healthiest weight yet and trust their body…beyond the scale. Learn more about HCC.Join Lindsey's Thrive Tribe email community#dietculture, #intuitiveeating, #ozempic, #weightlossjourney, #wellnesspodcast, #healthyhabits, #bodytrust, #sustainableweightloss, #midlifewellness, #ditchthediet, #nutritioncoach, #lindseykaszuba, #dawnversationspodcast, #mindbodyconnection, #realwellness, #healthylifestyle, #agingwell, #balancedliving, #habitsnothacks, #bodyrespect, #selfcare, #wellness #health

The balance between targeting tumor and sparing healthy liver is delicate. How do the experts do it? In this case-based review, Drs. Zach Berman (UC San Diego) and Tyler Sandow (Ochsner Health) join host Dr. Kavi Krishnasamy to walk us through real-world scenarios and share how they approach Y90 dose optimization. --- This podcast is supported by: Sirtexhttps://www.sirtex.com/ Medtronic Emprinthttps://www.medtronic.com/emprint --- SYNPOSIS First, the doctors review a case of HCC and discuss key lab values, like albumin, and their role in planning. They also break down how they manipulate variables like microsphere activity, perfusion density, and total dose to deliver a tumor dose of around 1,100 Gy. The doctors also challenge the standard perfused dose of 400 Gy for large tumors and share when they feel comfortable pushing beyond it. Next, they discuss nuances in treating portal vein tumor invasion and what decides which Vp classifications can be treated with Y90 or combination immunotherapy. A subsequent case involving a large central HCC tumor explores the risks of biliary stricture from high radiation and the challenge of missing tumor margins with overly selective catheterization. In the last case, the doctors discuss different scenarios in multifocal HCC liver lesions. Overall, the conversation explores different approaches based on tumor size, location, and patient liver function, and highlights the importance of multidisciplinary collaboration in optimizing patient outcomes. --- TIMESTAMPS 00:00 - Introduction and Case Overview01:28 - Patient Case Study - Hep C and Alcoholic Cirrhosis02:05 - Evaluating Liver Function and Treatment Approach04:50 - Tumor Dose and Perfusion Density15:49 - Portal Vein Tumor Invasion21:42 - Case Study: Large Central HCC Tumor Treatment22:19 - Challenges in Treating Large Central Tumors22:48 - Dosimetry Considerations and Biliary Strictures27:24 - Case Study: Assorted Multifocal HCC Lesions Scenarios

For this week's episode I'm bringing you something a little different, but of such importance that I had to share it with my Off the Record audience: The massive audit expansion of Medicare Advantage announced by CMS. In case you missed it, CMS in May rocked the mid-revenue cycle industry with the unveiling of a startling mandate. It will hire 2000 medical coders, beef up its audit technology, and expand its current limited auditing scope from 60 Medicare Advantage Plans to some 550 plans nationwide in an attempt to check widespread allegations of HCC upcoding. My colleague Jason Jobes has been closely following the news and presented this topic in June—the most attended webinar Norwood has ever hosted. This is a replay of that very well-received show. It covers: The evolving risk adjustment landscape and the rise of Medicare Advantage CMS broad and bold audit scope and strategy  Best practice techniques to survive in risk adjustment and avoid potential risks Jason refers to several slides during the presentation, which you don't necessarily need, but if you'd like to follow along or see the exact references and data we've posted them to the Norwood website with a link in the show notes. Enjoy the show!  Show notes and resources View the webinar slides here (free; requires registration) Read the full CMS audit announcement. 

Will single session Y90 become the standard of care for HCC and oligo-metastatic disease? Tune in to our third installment of Dosimetry University with interventional oncologists Drs. Tyler Sandow, Nima Kokabi, and Kavi Krishnasamy as they share their experiences and best practices in single session Y90 treatment. --- This podcast is supported by:Sirtexhttps://www.sirtex.com/ Medtronic Emprinthttps://www.medtronic.com/emprint --- SYNPOSIS The doctors discuss the application and workflow of single session Y90 therapy for primary and oligo-metastatic liver tumors. They discuss the latest data from various institutions, emphasizing reduced lung dose, lower time to treatment, improved cost-efficiency, and the advantageous safety profile associated with single session treatment. The discussion also covers ideal patient selection based on tumor location and vascular characteristics, the importance of cone beam CT, and how to identify red-flag features of vascular enhancement. Our panel then reviews key technical considerations for single session success, including the use of flow-modifying microcatheters, gelfoam, and strategies for flow redirection. The episode concludes with a case discussion to explore the best strategy for a large liver tumor, detailing the specifics of each treatment and the potential role of combined therapies to achieve better long-term outcomes. --- TIMESTAMPS 00:00 - Introduction 00:47 - Single Session Y90: Workflow and Benefits03:52 - Patient Selection04:31 - Tumor Location and Preferred Techniques14:31 - Reperfusion and Redirection Techniques 26:16 - Case Study: Large Tumor Treatment37:01 - Long-Term Outcomes and Surgical Considerations

SummaryIn this episode, the hosts discuss various pressing issues in healthcare, including the recent increase in CMS investigations into Medicare risk adjustment data, the challenges faced by providers in complying with insurance requests, and the implications of Medicaid eligibility changes. They also delve into the role of GLP-1 medications in weight loss and the importance of patient advocacy in navigating healthcare decisions. The conversation emphasizes the need for healthcare professionals to engage in meaningful dialogue with insurers and to advocate for their patients' needs.TakeawaysThe increase in CMS investigators for Medicare risk adjustment data is significant.Providers have the right to push back against unrealistic insurance requests.Medicaid is a state program designed for low-income individuals and specific groups.Work requirements for Medicaid eligibility are being proposed, affecting millions.GLP-1 medications are becoming popular for weight loss but come with high costs.Patients should advocate for themselves and ask questions about their treatment plans.Insurance companies often request excessive documentation, creating administrative burdens.The healthcare system is facing challenges with compliance and documentation accuracy.Understanding the implications of HCC coding is crucial for providers.The long-term effects of new medications are still largely unknown.